Microbiotica

Cambridge, United Kingdom Founded: 2016 • Age: 10 yrs
Live bacterial therapeutics and biomarkers are developed for multiple diseases.
Annual revenue - Latest available
Total funding $82.8M 3 rounds
Employees 42 Tracked headcount
Investors 7 Known backers
Products 2 Services tracked
Competitors 11 Brand Intelligence

About Microbiotica

Microbiotica is a company based in Cambridge (United Kingdom) founded in 2016 by Gordon Dougan and Trevor Lawley. Microbiotica has raised $82.84 million across 3 funding rounds from investors including Tencent, IP Group and Flerie. The company has 42 employees as of December 31, 2020. Microbiotica offers products and services including MB097 and MB310. Microbiotica operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Biogen, Alnylam and ATAI, among others.

  • Headquarter Cambridge, United Kingdom
  • Employees 42 as on 31 Dec, 2020
  • Founders Gordon Dougan, Trevor Lawley
  • Stage Minicorn
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Microbiotica Limited
  • Date of Incorporation 08 Jul, 2016
  • Jurisdiction CAMBRIDGE, ENGLAND
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $82.84 M (USD)

    in 3 rounds

  • Latest Funding Round
    $67 M (USD), Series B

    Mar 07, 2022

  • Investors
    Tencent

    & 6 more

  • Employee Count
    42

    as on Dec 31, 2020

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Microbiotica

Microbiotica offers a comprehensive portfolio of products and services, including MB097 and MB310.

Product name locked
Category locked
Primary

Co-therapy with KEYTRUDA for advanced melanoma treatment.

Product name locked
Category locked
Locked

Therapy for ulcerative colitis to improve patient outcomes.

People of Microbiotica

Headcount 50-200
Employee Profiles 29
Board Members and Advisors 13
Employee Profiles
People
Victor Okang
Senior Scientist
People
Trevor Lawley
Co-Founder & CSO
People
Ro Gardner
VP, Operations & Company Secretary
People
Tim Sharpington
CEO

Unlock access to complete

Board Members and Advisors
people
Hans Schikan
Non-Executive Chairman
people
Sam Williams
Director
people
Robert Tansley
Director
people
Carmine Circelli
Director

Unlock access to complete

Funding Insights of Microbiotica

Microbiotica has successfully raised a total of $82.84M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $67 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Microbiotica

Microbiotica has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Tencent, IP Group and Flerie.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Flerie is engaged in investing in biotech and pharmaceutical companies.
Locked Locked Locked
Venture capital co-investments are made in UK later-stage businesses.
Locked Locked Locked
Venture capital investments are made in life sciences and deep tech.
Locked Locked Locked
Premium access

Investor details for Microbiotica

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Microbiotica

Investments
Premium access

Investment portfolio details for Microbiotica

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Microbiotica

Premium access

Detailed financials for Microbiotica

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Microbiotica Comparisons

Microbiotica Primary company
Description
Live bacterial therapeutics and biomarkers are developed for...
Location
Cambridge, United Kingdom
Founded Year
2016
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
42
As of 2020
Premium access

Peer comparison for Microbiotica

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Microbiotica

Microbiotica operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Biogen, Alnylam and ATAI, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Therapeutics for genetic diseases are developed through targeted interventions.
Locked Locked Locked
Gene therapies for rare diseases including retinal dystrophies are developed.
Locked Locked Locked
Therapies for neurodegenerative and immunology disorders are developed.
Locked Locked Locked
RNA interference-based therapeutics are developed for multiple disorders.
Locked Locked Locked
A biopharmaceutical company accelerating innovative mental health treatments.
Locked Locked Locked
An AI-enabled platform is developed for infectious disease treatment.
Premium access

Detailed competitors of Microbiotica

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Microbiotica

Premium access

Complete news archive for Microbiotica

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Microbiotica

Microbiotica was founded in 2016.

Microbiotica is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.

Microbiotica is a funded company, having raised a total of $82.84M across 3 funding rounds to date.

As of Dec 31, 2020, the latest employee count at Microbiotica is 42.

Microbiotica was founded in 2016 and is headquartered in Cambridge, United Kingdom. Operations focus on the biotechnology sector, where gut bacteria associated with specific phenotypes are identified to support the development of live bacterial therapeutics and biomarkers. These efforts target inflammatory bowel disease, immuno-oncology, and gut epithelial barrier repair, with precision applied to phenotype linkages for therapeutic applications.

Microbiotica's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.

Microbiotica offers MB097 and MB310.

Microbiotica has 7 investors. Key investors include Tencent, IP Group, Flerie, British Patient Capital, and Cambridge Innovation Capital.

The valuation of Microbiotica is $37.34M as of May 2018.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available